Home › Research › Risk factors
Recent advances in neuroimaging of Alzheimer's disease and related dementias
Julie Ottoy, Nicole Owsicki, Murat Bilgel, Alexa Pichet Binette, Gemma Salvadó, Min Su Kang, David M. Cash, Michael Ewers et al.. Alzheimer s & Dementia, 2025-09-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
This review covers recent advances (2023-2024) in neuroimaging research into the pathophysiology, progression, and treatment of Alzheimer's disease (AD) and related dementias (ADRD). Despite the rapid emergence of blood-based biomarkers, neuroimaging continues to be a vital area of research in ADRD. Here, we discuss neuroimaging as a powerful tool to topographically visualize and quantify amyloid, tau, neurodegeneration, inflammation, and vascular disease in the brain. We examine the utility of neuroimaging for (1) tracking the spatiotemporal progression of pathology, (2) serving as the reference standard for validating novel fluid biomarkers, (3) characterizing disease heterogeneity, (4) exploring the role of brain networks in ADRD progression, and (5) evaluating biomarkers for better individualized estimates of treatment benefit. Finally, we discuss advances in radiotracer development and AD risk factors. By reviewing the most promising breakthroughs in the neuroimaging field, we hope to spark new ideas for future discoveries that will deepen our understanding of ADRD. HIGHLIGHTS: The diagnostic and staging criteria for Alzheimer's disease (AD) were updated in 2024. Despite robust harmonization methods for amyloid beta positron emission tomography (PET), parallel efforts for tau PET remain challenging. Larger anti-amyloid drug effects were seen at lower levels of amyloid and tau PET. Phosphorylated tau217 (p-tau217) is currently the most promising plasma biomarker to detect AD pathology. There are new tracer developments for alpha-synuclein, primary tauopathies, and inflammation.
What this study adds
Evidence grade: Low
This review describes how brain imaging is used to visualize and track amyloid, tau, neurodegeneration, inflammation and vascular disease in Alzheimer's and related dementias. It reports technical and biomarker advances, not a treatment or cure, and notes that tau PET harmonization remains challenging.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ottoy, J., Owsicki, N., Bilgel, M., Binette, A. P., Salvadó, G., Kang, M. S., et al. (2025). Recent advances in neuroimaging of Alzheimer's disease and related dementias. Alzheimer s & Dementia. https://doi.org/10.1002/alz.70648
Vancouver
Ottoy J, Owsicki N, Bilgel M, Binette AP, Salvadó G, Kang MS, et al. Recent advances in neuroimaging of Alzheimer's disease and related dementias. Alzheimer s & Dementia. 2025. doi:10.1002/alz.70648. PMID: 40922096.
BibTeX
@article{ottoy2025-40922096,
author = {Ottoy, Julie and Owsicki, Nicole and Bilgel, Murat and Binette, Alexa Pichet and Salvadó, Gemma and Kang, Min Su and Cash, David M. and Ewers, Michael and others},
title = {{Recent advances in neuroimaging of Alzheimer's disease and related dementias}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz.70648},
pmid = {40922096},
url = {https://doi.org/10.1002/alz.70648}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- HIGHLIGHTS: The diagnostic and staging criteria for Alzheimer's disease (AD) were updated in 2024.
- Despite robust harmonization methods for amyloid beta positron emission tomography (PET), parallel efforts for tau PET remain challenging.
- Larger anti-amyloid drug effects were seen at lower levels of amyloid and tau PET.
- Phosphorylated tau217 (p-tau217) is currently the most promising plasma biomarker to detect AD pathology.
- There are new tracer developments for alpha-synuclein, primary tauopathies, and inflammation.
Why it matters
This review describes how brain imaging is used to visualize and track amyloid, tau, neurodegeneration, inflammation and vascular disease in Alzheimer's and related dementias. It reports technical and biomarker advances, not a treatment or cure, and notes that tau PET harmonization remains challenging.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Evidence strengthLow
How this study scored 47/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 25 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 15.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 25 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Tobey J. Betthauser: h-index 34 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 16 institution(s) in 6 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40922096) |
| Free to read | 2 / 2 | Free to read |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 35.
Related studies in Risk factors from nearby years
Also in Risk factors
395 studies in the library are filed under Risk factors with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk factors hub.